Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Avan J Armaghani, Hyo Sook Han Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USACorrespondence: Avan J Armaghani Email avan.armaghani@moffitt.orgAbstract: Hormone receptor positive, human epidermal growth fact...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Armaghani AJ, Han HS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	pi3k pik3ca alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f0721596dfc64a26b674b5e4d84fb1a4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0721596dfc64a26b674b5e4d84fb1a4
record_format	dspace
spelling	oai:doaj.org-article:f0721596dfc64a26b674b5e4d84fb1a42021-12-02T12:09:28ZAlpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data1179-1314https://doaj.org/article/f0721596dfc64a26b674b5e4d84fb1a42020-11-01T00:00:00Zhttps://www.dovepress.com/alpelisib-in-the-treatment-of-breast-cancer-a-short-review-on-the-emer-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Avan J Armaghani, Hyo Sook Han Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USACorrespondence: Avan J Armaghani Email avan.armaghani@moffitt.orgAbstract: Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. There has been much advancement in the treatment of HR+/HER2 negative metastatic breast cancer (MBC), in particular the development of more tailored and targeted therapies. Recently, greater understanding of the role of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in breast cancer has led to the development of PI3K inhibitors, which have proven to be effective in the treatment of HR+/HER2 negative MBC. In this review, we will discuss the role of the PI3K/AKT/mTOR pathway in breast cancer and therapies that have been developed to inhibit PI3K. We will discuss in detail the development of PI3K inhibitor alpelisib, indications for use in HR+/HER2 negative MBC, safety and tolerability and the future direction of this therapy in the treatment of breast cancer.Keywords: PI3K, PIK3CA, alpelisibArmaghani AJHan HSDove Medical Pressarticlepi3kpik3caalpelisibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 12, Pp 251-258 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	pi3k pik3ca alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	pi3k pik3ca alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Armaghani AJ Han HS Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
description	Avan J Armaghani, Hyo Sook Han Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USACorrespondence: Avan J Armaghani Email avan.armaghani@moffitt.orgAbstract: Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2 negative) breast cancer accounts for over 70% of all breast cancers. There has been much advancement in the treatment of HR+/HER2 negative metastatic breast cancer (MBC), in particular the development of more tailored and targeted therapies. Recently, greater understanding of the role of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in breast cancer has led to the development of PI3K inhibitors, which have proven to be effective in the treatment of HR+/HER2 negative MBC. In this review, we will discuss the role of the PI3K/AKT/mTOR pathway in breast cancer and therapies that have been developed to inhibit PI3K. We will discuss in detail the development of PI3K inhibitor alpelisib, indications for use in HR+/HER2 negative MBC, safety and tolerability and the future direction of this therapy in the treatment of breast cancer.Keywords: PI3K, PIK3CA, alpelisib
format	article
author	Armaghani AJ Han HS
author_facet	Armaghani AJ Han HS
author_sort	Armaghani AJ
title	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
title_short	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
title_full	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
title_fullStr	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
title_full_unstemmed	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
title_sort	alpelisib in the treatment of breast cancer: a short review on the emerging clinical data
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f0721596dfc64a26b674b5e4d84fb1a4
work_keys_str_mv	AT armaghaniaj alpelisibinthetreatmentofbreastcancerashortreviewontheemergingclinicaldata AT hanhs alpelisibinthetreatmentofbreastcancerashortreviewontheemergingclinicaldata
_version_	1718394665238003712

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

Ejemplares similares